Preferences of Persons with or at Risk for Hepatitis C for Long-Acting Treatments.
Ethel D WeldJacqueline AstemborskiGregory D KirkMark S SulkowskiKatz StephanieRichard RothmanSunil S SolomonGail V MatthewsYu-Hsiang HsiehMalvika VermaGiovanni TraversoSusan SwindellsAndrew OwenJordan FeldCharles FlexnerShruti H MehtaDavid L ThomasPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)
These data point to high acceptability of long-acting treatments, which for a substantial minority, might even be preferred to pills for the treatment of HCV infection. Long-acting treatments for HCV infection might contribute to global efforts to eliminate hepatitis C.